[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Comment & Response
August 2016

Gene Expression Classifier Testing and the Surgical Decision-Making Process for Patients With Thyroid Nodules

Author Affiliations
  • 1Veracyte, Inc, South San Francisco, California
JAMA Otolaryngol Head Neck Surg. 2016;142(8):806-807. doi:10.1001/jamaoto.2016.0200

To the Editor Noureldine and colleagues1 found that molecular testing with the Afirma gene expression classifier (GEC) did not have a significant effect on the surgical decision-making process for patients with thyroid nodules who presented for surgical consultation. However, this study1 evaluates the test’s performance using an approach that runs counter to the test’s intended use.

First Page Preview View Large
First page PDF preview
First page PDF preview